Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies

Pregnancy Related Clinical Trial

— CAREFOL-HT  

Official title:

Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies (CAREFOL-HT)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05434195
• Other study ID #: 295830
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2021
• Est. completion date: June 2024

Study information

• Verified date: May 2022
• Source: University of Oxford
• Contact: Annabelle Frost, MD
• Phone: 01865 572833
• Email: carefol-ht[@]cardiov.ox.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study background High blood pressure during pregnancy is a worldwide health problem that can be dangerous to mothers and commonly causes premature birth and small babies. There is also growing evidence that mothers who suffer from high blood pressure in pregnancy, and their babies, have a higher risk of high blood pressure and cardiovascular disease later in life. Previous studies have revealed detrimental changes in the structure and function of the heart and blood vessels of mothers, and their babies, who experience this common complication. These changes may explain their increased risk of later disease. The investigators have also learned through previous studies that tetrahydrobiopterin (BH4), a molecule that has a role in blood vessel health, plays an important role in stabilising blood vessel function. Lower levels of BH4 are evident in both the placenta and the umbilical cord from mothers with high blood pressure. We, therefore, want to investigate how closely BH4 levels are related to clinical features of pre-eclampsia and whether altering levels of BH4, using a nutritional supplement, improves features of the disease such as blood vessel function. To do this, the investigators need to compare the levels of BH4 between mothers with pre-eclampsia, those taking the supplement and those without pre-eclampsia. The investigators also compare how the heart and blood vessels look and function in these groups using ultrasound methods, including echocardiography and fetal sonography. Study objectives CAREFOL-HT will assess how levels of BH4 differ in pregnant women with high blood pressure and if this is reflected in functional changes in the heart and blood vessels of these women. The investigators will also determine whether changing levels of BH4, using a tetrahydrofolate supplement (5-MTHF), changes blood vessel function.

Description:

High blood pressure during pregnancy is a world-wide health problem that can be dangerous to mothers, and commonly causes premature birth and small babies. There is also growing evidence that mothers who suffer from high blood pressure in pregnancy and their babies both have a higher risk of high blood pressure and cardiovascular disease in later life. Previous studies have revealed detrimental changes in the structure and function of the heart and blood vessels of mothers and their babies who experience this common complication which may be important in understanding the subsequent increased risk of later disease. The investigators have also learned through previous work carried out by our research group that certain biological processes may be disturbed in women with high blood pressure in pregnancy. One of these processes involves a molecule called tetrahydrobiopterin (also known as BH4) which is required for the correct functioning of blood vessels. Supplementation with biologically-active forms of reduced folate are able to increase the levels of this molecule and can reverse the changes caused by high blood pressure in pregnant mice, and in cultured human endothelial cells. These particular folate supplements are safe and approved for use in pregnancy, but are not widely used as they are more specialised and currently less available than folic acid, the oxidized form of folate that is widely used for supplementation in pregnancy. However, folic acid does not have the same effects as the specific biologically-active form of reduced folate (tetrahydrofolate), because folic acid requires enzymatic conversion within the body in order to generate the biologically-active form of reduced folate. Whilst the use of folic acid appears to be sufficient in most cases to increase folate levels in the prevention of fetal abnormalities such as neural tube defects, the conversion of folic acid to its biologically-active reduced form may be itself deficient or detrimental in women with preeclampsia, and does not increase tetrahydrobiopterin levels. Indeed, folic acid treatment has been found to be ineffective in a large clinical trial to improve high blood pressure in pregnancy women. This clinical trial will investigate the levels of biologically-active forms of reduced folates. As a way to increase the levels of tetrahydrobiopterin, in pregnant women with high blood pressure, women participating in the trial will take either a low dose or a high dose of a biologically-active form of reduced folate (tetrahydrofolate supplement) until delivery of their baby. A further group of women with high blood pressure will be recruited and will take a placebo. Blood tests will be taken and measurements performed to evaluate the heart and blood vessels of the participating women and their babies upon entry into the study and again at the time of birth. The investigators will also collect the umbilical cord and placenta tissue samples once the baby has been born, so that the investigators can assess blood vessel cell function following tetrahydrofolate supplementation in laboratory studies. In addition to the groups of women with high blood pressure, the investigators will also invite a group of women with an uncomplicated pregnancy to take part, as a comparison group, these women will not receive any supplementation. The investigators aim to investigate how levels of factors in the folate pathway differ in pregnant women with high blood pressure and if this is reflected in functional changes in the heart and blood vessels of these women. The investigators also aim to study whether this tetrahydrofolate supplement can increase the levels of tetrahydrobiopterin and if this improves blood vessel function. If successful, the investigators hope that the results of this study will enable us to design and conduct a larger study in future in order to test whether taking this tetrahydrofolate supplement will stop or reverse the changes caused by high blood pressure in pregnancy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 128
• Est. completion date: June 2024
• Est. primary completion date: June 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria (Preeclampsia individuals):

• Diagnosed with preeclampsia, as defined in Section 8.1, at <34 weeks' gestation within the last 48 hours and with no delivery planned within the next week
• Receiving antenatal care in the John Radcliffe Hospital
• Participant is willing and able to give informed consent for participation in the study
• Age >18 and =45 years Exclusion Criteria (Preeclampsia individuals): The participant may not enter the study if ANY of the following apply: Maternal
• History of cardiac impairments including uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure or valve disease
• History of preexisting chronic renal disease
• Contraindication to taking folate related supplements
• Folate supplementation in excess of 400mcg in the third trimester
• Low vitamin B12 levels (<148 pmol/L)
• Intake of either proton pump inhibitors or anti-epileptic drugs
• Organ dysfunction Fetal
• Any known trisomy
• Fetus with congenital heart defect
• Fetus at a high risk of heart disease
• Known infection of fetus
• Known severe anaemia

Inclusion Criteria (Normotensive individuals):

• Participant is willing and able to give informed consent for participation in the study
• Age >18 and =45 years
• Normotensive, blood pressures <140/90 throughout antenatal period
• Less than 2 moderate risk factors for hypertensive disease in pregnancy according to the NICE guideline for management of hypertension in pregnancy
• SFlt/PIGF ratio <35 Exclusion Criteria (Normotensive individuals): The participant may not enter the study if ANY of the following apply: Maternal
• Diagnosis of hypertensive disorder of pregnancy
• Use of beta blockers such as atenolol or equivalent
• History of cardiac impairments including uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure or valve disease
• History of preexisting chronic renal disease Fetal
• Any known trisomy
• Fetus with congenital heart defect
• Fetus at a high risk of heart disease
• Known infection of fetus
• Known severe anaemia

Related Conditions & MeSH terms

• Eclampsia
• Hypertension, Pregnancy-Induced
• Pre-Eclampsia
• Pregnancy Induced Hypertension
• Pregnancy Related

Intervention

Dietary Supplement:
• Arcofolin® 5-Methyltetrahydrofolate
5-methyltetrahydrofolate (5-MTHF) is the biologically active form of reduced folate, which can increase BH4 availability. 5-MTHF is available as a nutritional vitamin (Merck & Cie) for human use including during pregnancy. Two out of three preeclamptic study groups will receive 5-MTHF - one at a low dose and the other at a high dose.
• Arcofolin® Placebo
The placebo, this consists of the same excipients as 5-MTHF, microcrystalline cellulose and silica with no active ingredient.

Locations

Country	Name	City	State
United Kingdom	Cardiovascular Clinical Research Facility	Oxford	Oxfordshire
United Kingdom	Oxford University Hospitals NHS Foundation Trust	Oxford	Oxfordhsire

Sponsors (4)

Lead Sponsor	Collaborator
University of Oxford	British Heart Foundation, Merck & Cie, National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the change of maternal circulating BH4 biomarkers levels at baseline to prior to delivery.	Levels of BH4, Dihydrobiopterin (BH2), tetrahydrofolate, dihydrofolate reductase (DHFR), GTP cyclohydrolase I (GTPCH) will be assessed.	Baseline (gestation approx. 28- 34 weeks) and prior to delivery
Primary	To assess the change of maternal nitric oxide levels at baseline to prior to delivery.	Levels of nitric oxide will be assessed in maternal serum samples.	Baseline (gestation approx. 28- 34 weeks) and prior to delivery
Primary	To assess the levels of BH4 biomarkers in umbilical cord blood.	Levels of BH4, Dihydrobiopterin (BH2), tetrahydrofolate, dihydrofolate reductase (DHFR), GTP cyclohydrolase I (GTPCH) will be assessed in cord blood serum.	At delivery
Primary	To assess the levels of BH4 biomarkers in placenta.	Levels of BH4, Dihydrobiopterin (BH2), tetrahydrofolate, dihydrofolate reductase (DHFR), GTP cyclohydrolase I (GTPCH) will be assessed in placental tissues.	At delivery
Primary	To assess the levels of nitric oxide levels in umbilical cord blood.	Levels of nitric oxide will be assessed in cord blood serum.	At delivery
Primary	To assess the levels of nitric oxide levels in placenta.	Levels of nitric oxide will be assessed in placental tissues.	At delivery
Secondary	To assess whether maternal BH4 biomarkers levels are correlated with changes in the offspring.	Levels of folates, BH4 BH2, tetrahydrofolate, DHFR, and GTPCH will be assessed	Maternal: at baseline (gestation approx. 28- 34 weeks) and prior to delivery Umbilical cord and placenta: immediately after delivery
Secondary	To assess whether BH4 biomarkers levels are correlated with improved angiogenesis profile of maternal blood-derived endothelial cell forming colonies (ECFCs). changes in in-vitro maternal and fetal vascular function.	Angiogenesis profile of ECFCs (tube length, diameter, total area and duration for regression) will be determined via in vitro tube formation assay.	At baseline (gestation approx. 28- 34 weeks) and prior to delivery
Secondary	To assess whether BH4 biomarkers levels are correlated with improved angiogenesis profile of human umbilical vein endothelial cells (HUVECs).	Angiogenesis profile of HUVECs (tube length, diameter, total area and duration for regression) will be determined via in vitro tube formation assay.	At delivery
Secondary	To assess whether BH4 biomarkers levels are correlated with circulating angiogenic molecules (soluble fms-like tyrosine kinase-1 and placental growth factor).	Measurement of sFlt-1 and PlGF will be measure in serum samples in the clinical biochemistry laboratory.	At baseline (gestation approx. 34 weeks) and prior to delivery.
Secondary	To assess whether BH4 biomarkers levels are correlated with in-vivo flow-mediated dilatation (FMD) changes.	Brachial artery FMD induced by reactive hyperemia to assess vascular endothelial function.	At baseline (gestation approx. 34 weeks) and prior to delivery.
Secondary	To assess whether BH4 biomarkers levels are correlated with peripheral blood pressure changes.	Flow mediated dilatation, peripheral blood pressure, left and right ventricular mass and volumes and cardiac diastolic function.	At baseline (gestation approx. 34 weeks) and prior to delivery.
Secondary	To assess whether tetrahydrofolate levels are associated with cardiac remodelling.	Echocardiography will be performed and left and right ventricular mass and volumes and cardiac diastolic function will be investigated.	At baseline (gestation approx. 34 weeks) and prior to delivery.
Secondary	To investigate the acceptability and feasibility of taking the supplementation during pregnancy via questionnaire.	All participants will also be asked to complete a questionnaire assessing the acceptability of 5-MTHF supplementation. This questionnaire can be completed at any point before discharge.	After delivery

External Links

•   CAREFOL-HT Study